Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Bill Aims For Trolls, But Will It Snare Rx Firms Instead?

Executive Summary

Rep. Bob Goodlatte’s Innovation Act would delay discovery, require more information to file suits, which could increase the time and expense of pursuing infringement cases.

You may also be interested in...



Drug Firms Ask Senate For Narrow Patent Troll Bill

“One-size-fits-all” patent troll bill will harm innovators, Johnson & Johnson’s chief IP counsel tells Senate hearing.

Patent Troll Bill Clears House; Provisions Problematic For PhRMA Remain

Amendments make things a little better for drug firms as attention now shifts to the Senate version.

Generic Manufacturers May Gain Edge In New Patent Challenge Procedure At PTO

Apotex’s challenge of Alcon’s Vigamox patent put PTO’s new inter partes review proceeding in the spotlight; 45 petitions have been filed in the biopharma sector.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel